DPP-4 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2025

Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.

Jun Hwa Hong et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 235 people · 2025

Randomised comparison

Probably lowered glycemic control

−0.88percentage points−1.07 to −0.68

As reported

difference −0.88 %, 95% CI −1.07 to −0.68

One number in the abstract

the abstract, start to end

with a least squares mean difference of -0.88% (95% confidence interval -1.07

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.88−1.07 to −0.68
DPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

3 papers cite it

2024
2025
this papertrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 39375869